Insurance by BogdanovaThe Encyclopedia of Insurance and Risk Science

RESEARCH DOSSIER

Cross-Border Health Insurance Portability and Travel Coverage

Abstract. Cross-border health coverage is a coordination problem spanning legal eligibility, territorial healthcare delivery, provider reimbursement, insurance contracts, and the timely settlement of medical claims. This monograph examines temporary travel, planned treatment abroad, cross-border residence, migrant transitions, and commercial medical assistance through comparative analysis of European Union legislation, United Kingdom reciprocal rights, Australian reciprocal healthcare agreements, Canadian public coverage, United States Medicare provisions, international labor standards, and original scholarship. It differentiates portable statutory entitlements from emergency benefits under reciprocal systems, reimbursement of planned foreign treatment, and privately insured travel risk. The study reconstructs the payer–provider–patient claims sequence, analyzes financial incidence and exposure denominators, and presents explicitly hypothetical sensitivity calculations. European Commission reporting indicates that legal rights coexist with limited use of some planned-care reimbursement routes and persistent information, liquidity, and administrative obstacles. The findings identify entitlement continuity, provider acceptance, preauthorization, tariffs, exclusions, direct settlement, health-data governance, and appeals as independently observable determinants of actual protection. The original contribution is a source-grounded comparative synthesis and falsifiable measurement agenda. No original proprietary theory, clinical trial, patient-level dataset, or country-universal legal opinion is claimed.

Keywords: Cross-border health insurance; portability; European Health Insurance Card; EHIC; S1; S2; reciprocal health care; travel medical insurance; emergency treatment; medical evacuation; migrant health coverage; claims reimbursement; patient mobility; health financing; financial protection; coordination of benefits; insurance law; cross-border jurisdiction; data protection; health insurance economics.

Introduction: coverage across territorial health systems

Health care is delivered at a place, often financed by a territorially organized institution, and consumed by a person whose residence, employment, citizenship, family ties and itinerary can change. Cross-border health insurance portability concerns the persistence and enforceability of funding rights when those coordinates diverge. The unit of inquiry is therefore not simply a traveler or an insurance card. It is a specified entitlement, attached to an eligible person, defined for a health event, available from a provider in a jurisdiction, and settled under an identified financing rule.

The 2025 WHO–World Bank monitoring report distinguishes essential service coverage and financial protection from out-of-pocket spending. Cross-border portability adds a geographical and procedural dimension to those established concepts: a person can be nominally insured at home and still face a large unreimbursed bill, a delayed admission, or an unavailable specialist while abroad. Conversely, an uninsured visitor may receive emergency care under a local legal duty, while the eventual bill remains that visitor's responsibility. Access to treatment and financing of treatment must be evaluated separately.

The research addresses three connected questions. First, when is an existing domestic health entitlement recognized or made financially effective in another country? Second, how do urgent medical needs, private travel contracts and emergency assistance respond when public coordination does not meet every cost? Third, which claims procedures, legal fora and evidentiary requirements convert eligibility into payment? The analysis is international, with detailed primary-source examination of jurisdictions where current official legal and administrative texts could be checked. It identifies broader global patterns only at the level supported by comparative scholarship and multilateral publications.

A principal methodological commitment is to disaggregate five often conflated events: recognition of the person as eligible; acceptance of the chosen provider and service; calculation of the allowable amount; immediate liquidity or direct payment; and final reimbursement. This is an analytical decomposition of existing legal and insurance operations, not a proposed proprietary framework. It permits transparent examination of gaps between an entitlement on paper and protection at the point of treatment.

Foundations and source-critical history

Scientific object and basic definitions

A portable health insurance entitlement is a claim to covered treatment or to coverage-related reimbursement whose validity is recognized away from the ordinary territory of affiliation under applicable law or contract. Portability can mean that the competent insurer retains financial responsibility while the place-of-treatment system supplies care. It can also mean that a patient initially pays abroad and later recovers an eligible amount from an insurer at home. Those arrangements yield different incentives, cash requirements, and complaint procedures.

A temporary stay is a period abroad that does not by itself establish ordinary residence for the health financing scheme. Residence is a legally relevant status assessed under applicable coordination and national rules, rather than inferred solely from a travel document or the number of nights spent abroad. Planned care is treatment for which the patient travels with a view to obtaining the service. Medically necessary treatment during a temporary stay refers to care that cannot appropriately wait for return, considering the medical need and planned duration. Emergency care is a clinically urgent subset; the relevant legal test can be broader than an immediately life-threatening event.

Travel medical insurance is a private or group contract covering specified medical events occurring during travel. Travel disruption insurance responds to cancellation, delay, or interruption triggers; medical evacuation insurance covers transportation under defined medical and operational conditions. As the CDC Yellow Book insurance chapter explains, these products can be bundled or bought separately, and a generic travel-related benefit does not automatically contain each component. Private medical insurance marketed to expatriates or long-term international residents involves further underwriting and residency conditions that may differ from short-duration travel insurance.

A treaty, an EU regulation, a nationally administered public entitlement, an insurance policy, and a medical assistance promise create different categories of enforceable rights. A statutory coordination instrument may bind participating authorities subject to its scope. An individual contract binds its parties within governing law and specific terms. A medical assistance company may coordinate logistics as an agent of an insurer, but the allocation of coverage liability remains a separate question.

The territorial architecture of health financing

National health financing institutions pool contributions, taxes or premiums against an expected set of claims. The enrolled population, geographic provider arrangements and benefit package delimit anticipated spending. Territoriality historically simplified accounting, service planning and oversight. As cross-border residence and travel grew, entitlement rules and patient behavior began to operate across those boundaries.

In their typology of cross-border patient mobility, Glinos, Baeten, Helble, and Maarse (2010) distinguish motivations for seeking planned treatment abroad and means of payment. Their defined subject is a patient who intentionally travels for medical care, rather than a tourist unexpectedly needing treatment. This distinction is essential: evidence about medical tourism cannot be used without adjustment to estimate the risk or outcomes of unforeseen emergencies among all international travelers.

Research on formal contracting also shows that a purchaser can deliberately arrange services with foreign providers. In six-country cross-border contracting research, Glinos, Baeten, and Maarse (2010) examined contracting and patient mobility as distinct institutional pathways. Organized purchasing may improve payment predictability compared with unarranged treatment, but its performance depends on negotiated tariffs, referral selection, clinical quality and follow-up. The presence of a border changes the transaction's legal and administrative conditions even when the clinical intervention is identical.

Historical emergence of coordination and patient rights

European social security coordination developed to allow movement without simply extinguishing rights associated with an insured person's competent system. Regulation (EC) No. 883/2004 codified rules identifying applicable legislation and circumstances in which benefits in kind could be provided through another participating institution. Its implementing Regulation No. 987/2009 specifies documentation and financial settlement procedures. The European Health Insurance Card operationalizes temporary-stay evidence of entitlement in participating settings.

A separate European legal development concerned planned cross-border care and patients' rights. The adoption of Directive 2011/24/EU established conditions for reimbursement and information when patients obtain eligible care in another Member State. Peeters (2012), in a legal analysis of the Directive, situates these rules in the development of cross-border patient rights and institutional cooperation. The two European routes overlap in subject matter, yet differ fundamentally in authorization, permissible providers, tariffs, and initial payment.

The United Kingdom's post-EU-exit arrangements preserve important reciprocal mechanisms through particular legal instruments. The NHS GHIC and EHIC guidance describes medically necessary state healthcare in eligible destinations and specific qualifying rules. Australia maintains eleven country-specific reciprocal healthcare agreements, documented in Services Australia's agreement directory. Canada handles travel and interprovincial obligations through provincial and territorial plans described in Health Canada's coverage guidance. These examples demonstrate that different political and institutional systems can coordinate care without using the same legal instruments.

At the international labor level, ILO Convention No. 157 addresses maintenance of social security rights, including systems whose branches cover medical care. Treaty ratification, the particular branch of protection, and implementing measures remain crucial. In particular, the Convention's explicit portability language for certain cash benefits cannot simply be generalized into a universal right to free treatment abroad.

Evidence hierarchy and prior scholarship

The highest specificity for a legal entitlement normally comes from operative legislation, binding implementing rules, competent administrative decisions, and relevant verified contract wording. Official public guidance is strong evidence about administration but may simplify exceptions. Academic research clarifies causal mechanisms, policy history, empirical uptake and institutional context; it cannot replace the law governing an individual claim.

Legido-Quigley and colleagues (2012) examined actors, arrangements, institutional settings, processes and context in cross-border patient mobility research. The study provides a useful scholarly perspective on why identical legal permissions can produce unequal institutional results. This monograph uses that established multidimensional observation while examining a broader population that includes emergency travelers, migrants and insured residents. Claims about countries, years and outcomes are restricted to the source actually examined.

The WHO World Report on Refugees and Migrants (2022) documents legal status, language, discrimination, administrative access, health literacy and financial obstacles. Its evidence also cautions that comparative data remain fragmented. Accordingly, an apparent country difference in reported foreign claims may reflect different eligibility criteria and reporting systems rather than superior protection. The following chapters preserve this inferential distinction.

Portability and coordination rules

Applicable insurance system, residence and entitlement

The first issue is the competent scheme. Under European coordination, rules determine which Member State's social security legislation applies, generally to avoid simultaneous obligations and gaps created solely by cross-border work. Worker posting, frontier work, dependent family status, pension status and ordinary residence can change which institution is competent. A visitor possessing an EHIC does not acquire a new universal insurance plan through the card.

The Your Europe residence and health-cover guidance distinguishes students, posted workers, pensioners and people moving residence, including circumstances in which registration with an S1 form is appropriate. The European Commission's EHIC entitlement explanation expressly cautions that a person making another country their habitual residence should examine S1 registration rather than relying on the travel card. Eligibility must be established for a legally defined person, benefit and period.

For comparative research, the eligibility file should record nationality where legally relevant, insured status, country of affiliation, habitual residence, employment or pension category, dependent status, the applicable agreement, and exact travel dates. Those attributes often have different evidentiary importance. A passport alone rarely proves who bears medical costs; an insurance card can establish entitlement but cannot establish that every particular service is included.

European social security coordination: temporary stay

Article 19 of the social-security coordination regulation provides necessary benefits in kind during a stay in another covered Member State, supplied by the institution of the place of stay according to the conditions of the host system and on behalf of the competent institution. Medical necessity is evaluated with the nature of treatment and expected length of stay in view. This legal test includes important care needs beyond accidents, potentially covering aspects of ongoing conditions where the treatment must be supplied during the stay.

Article 25 of the implementing coordination regulation governs proof of entitlement and reimbursement when costs are borne by the patient. The document presented can be the EHIC or an appropriate replacement proof. Reimbursement may be sought through the host institution under its rates or through the competent institution under the specified procedures. Consequently, the same treatment can involve direct institutional settlement, a patient claim, or a mixed payment sequence.

The official temporary-stay restrictions clarify that the EHIC excludes private-sector treatment outside the relevant public system, planned treatment as the purpose of travel, and transport home after an accident or serious illness. It also notes important nationality-related restrictions in some participating countries. The Commission's EHIC guidance states that services are on the same terms and costs as for people insured in the place of treatment, which may include patient charges. A rule of equal treatment in a host scheme is not a promise of zero cost.

Planned treatment under the S2 route

Article 20 of Regulation No. 883/2004 deals with travel for the purpose of obtaining benefits in kind. Authorization of planned treatment depends on statutory conditions, including that treatment falls within the competent scheme's benefits and cannot be provided within a medically justifiable period in relevant circumstances. This is a legally structured authorization decision, with evidence and review requirements.

The official S2 application guidance describes the S2 document as proof of authorization and explains that an institution may arrange payment with the counterpart abroad. Treatment under this route is ordinarily connected to the rules and tariffs of the country of treatment. Patients may nonetheless face lawful contributions, services outside eligibility, travel costs and administrative requirements. The S2 is not interchangeable with a card for unplanned temporary-stay care.

A study of planned care should record the diagnosis and indication, availability and waiting time at home, authorization application date, decision date, treatment date, eligible treatment provider, host reimbursement schedule, and whether direct settlement was actually offered. These data allow researchers to distinguish denial of an entitlement from ordinary administrative delay, provider refusal or costs associated with travel.

Patient-rights reimbursement under Directive 2011/24/EU

Under Article 7 of the Cross-Border Healthcare Directive, reimbursement generally relates to services for which the person is entitled to coverage at home and is capped by the amount the home system would assume for that care, without exceeding the actual cost. Member States may adopt more generous provisions. Article 8 provides restricted circumstances in which prior authorization may be required, such as certain hospital or highly specialized care, together with procedural protections.

The Directive's route frequently places more of the initial payment obligation on the patient. A home tariff below the foreign provider's charge can generate a predictable residual. If the home plan does not cover the intervention, merely receiving it in another Member State does not create a reimbursement entitlement. Patients should compare this route with social-security coordination before treatment, because apparently similar planned procedures can have different financial consequences.

The Commission's 2022 implementation report found improved transparency and more consistent recognition of rights, alongside limited use and barriers associated with awareness, reimbursement uncertainty and administrative complexity. The supporting 2022 evaluation discussed approximately 300,000 annual reimbursement requests in the period reviewed. These requests are a particular administrative outcome and cannot be used as the denominator for all European medical travel or all EU insured persons receiving necessary care during visits.

United Kingdom, Australian and Canadian arrangements

The NHS guidance on GHIC describes UK-issued arrangements for necessary healthcare on temporary visits under the applicable eligibility and destination rules. The cards provide a means of accessing public healthcare under locally applicable conditions. They do not pay for private treatment, repatriation or every rescue service. Nationality and destination distinctions can affect access, including in Switzerland, and must be checked against current rules rather than inferred from the card's name.

Australia's reciprocal agreement list names Belgium, Finland, Italy, Malta, the Netherlands, New Zealand, Norway, Ireland, Slovenia, Sweden and the United Kingdom. The agreements provide medically necessary treatment under agreement-specific conditions, not identical universal benefits. The Australian travel advisory emphasizes copayments, exclusions and absence of evacuation coverage. Some inbound visitor categories, permitted service types and duration rules differ by partner country. A proper comparative table must retain the individual bilateral instrument as the unit of legal evidence.

In Canada, public health benefits are administered by provincial or territorial schemes. The federal overview of provincial coverage describes interprovincial emergency care continuity and generally limited out-of-country emergency reimbursement, frequently assessed against what a home province would have paid. The gap between domestic and foreign tariffs can be substantial. The federal summary is an entry point for analysis; any definitive individual determination requires the governing provincial rules, eligibility dates and service classifications.

United States Medicare and international labor standards

Medicare's official overseas-coverage rules explain that original Medicare generally does not cover foreign healthcare, subject to specified circumstances such as certain border-related or transit situations. Some Medigap products contain distinct foreign-travel emergency coverage, but plan selection and limits are material. It would be erroneous to describe all U.S. health insurance as nonportable on the basis of Medicare alone: employer plans, individual plans and specialist travel contracts require separate policy examination.

ILO's maintenance-of-rights convention provides a multilateral legal basis for understanding portability as part of social security coordination. It includes medical care among branches of protection in its scope, subject to applicable state commitments and agreements. The treaty is useful evidence for international normative history; it is not an empirical measurement of healthcare delivered or a blanket entitlement for every migrant.

Comparative eligibility and payment matrix

Arrangement Typical activating condition Immediate access rule Financial settlement Important residual risk
EU EHIC / temporary-stay coordination Necessary healthcare during eligible temporary stay Participating state providers, host-system conditions Host and competent institutions, or patient reimbursement Copayments, private providers, rescue and repatriation
EU S2 planned-care coordination Prior authorization for eligible planned care Authorized provider and treatment Coordination route, potentially institution-to-institution Unapproved services and ancillary costs
Directive 2011/24/EU Home-covered care abroad, subject to applicable conditions Patient obtains treatment within domestic and host rules Often patient pays, then home-tariff reimbursement Up-front liquidity, tariff gap, denied application
UK GHIC / EHIC Qualifying necessary healthcare in eligible destinations State-system participation Applicable reciprocal route Destination exceptions and repatriation
Australian reciprocal agreement Qualifying visitor, partner-country and necessary-care conditions Public services under bilateral terms Agreement-specific public settlement Service exclusions and evacuation
Canadian provincial/territorial plan overseas Eligible insured traveler and applicable emergency-care rules Foreign provider decides service and billing Limited provincial reimbursement under governing plan Large foreign price versus domestic tariff difference
U.S. Medicare overseas Particular statutory exception Provider and beneficiary eligibility Covered exception-specific claim Broad ordinary foreign-care exclusion
Commercial travel medical contract Valid policy, covered travel, covered event and exclusions Contractual network or reimbursement pathway Insurer, administrator or patient claim Deductibles, caps, exclusions, documentation and cash needs

This matrix identifies mechanisms rather than making a uniform current-country legal determination. Eligibility can change by residence, policy year, partner country, contractual endorsement, medical event and timing. The critical comparative distinction is the identity of the payer and the basis for that payer's obligation.

Emergency and travel benefits

Necessary healthcare, emergency care, and planned care

A person can require non-elective care during an extended trip even when the condition existed before departure. Under European temporary-stay coordination, legally relevant necessity considers whether postponement until the planned return is medically feasible; a simplistic accidents-only description is incorrect. Under an individual private travel policy, however, a preexisting-condition clause or stability period may be decisive even when immediate treatment is medically appropriate.

Clinical urgency and insurance admissibility must thus be documented independently. A provider's duty to treat, a clinician's assessment that a procedure is necessary, and an insurer's obligation to reimburse are different determinations. A denial because the condition was preexisting, for example, requires inspection of the exact contract wording and governing consumer law; it should not be inferred from a medical diagnosis alone.

The CDC travel insurance distinction separates health treatment costs from interruption and evacuation. The CDC advice for illness abroad recommends anticipating advance payment, retaining bills and recognizing that insurer assistance and provider acceptance differ. These sources describe ordinary risk-management practice, not minimum guaranteed benefits in all marketed products.

Private travel health and medical evacuation coverage

A travel medical policy can reimburse emergency consultations, diagnostics, inpatient episodes, specified pharmaceuticals and sometimes follow-up, each subject to a schedule. Evacuation benefits may cover medically indicated transfer to an appropriate facility or home repatriation when covered criteria and approval procedures are satisfied. The difference between transfer to the nearest appropriate facility and transport to a preferred home hospital is economically significant; policy wording controls.

Under a cashless or direct-billing agreement, an assistance network may issue a guarantee of payment to a hospital after confirming eligibility. Otherwise the patient may need to fund the invoice and submit a claim. Even when direct billing is advertised, exceptions may arise for non-network providers, excluded procedures or benefits outside limits. Failure to obtain preauthorization can influence payment where contractually required, but emergency exceptions and governing law must be assessed before characterizing a claim.

A benefit table should identify maximum medical benefit, evacuation limit, per-condition or per-trip restrictions, territorial scope, covered trip duration, deductible, coinsurance, waiting or stability periods, age or activity restrictions, provider network and duty to contact the assistance service. No single advertised aggregate coverage figure conveys all those financial consequences.

Contractual triggers, exclusions and assistance networks

Insurers may define a covered journey by a departure date, distance from residence, country of residence, scheduled return, permitted duration and policy purchase timing. Certain occupations, sports, high-altitude travel, cruising or preexisting illnesses may require endorsements or separate coverage. Public-health emergencies may be treated differently from individual accidental injury. Each question requires the operative policy version.

The NAIC travel-insurance regulatory overview documents the U.S. Travel Insurance Model Act and differing state enactment. It cannot establish that the same rule governs every state or product. In Europe, EIOPA's distribution guidance emphasizes customer information and insurance-product distribution responsibilities, including cross-border distribution. Insurer authorization, intermediary licensing, and contract governing law may affect who may market and service insurance, but they must be investigated for each market.

Assistance arrangements create an operational distinction between the party that answers the emergency hotline and the party that bears risk. Some networks are service providers paid through assistance fees; others operate as administrators or agents. Claims researchers should identify whether service failures led to medical delay, provider refusal, out-of-pocket payment, or eventual indemnity denial. Aggregating these into a single 'claim rejected' outcome conceals material mechanisms.

Medical bills, deductibles, coinsurance and currency risk

Consider an explicitly hypothetical illness abroad producing a $26,000 eligible hospital bill. A policy with a $500 per-event deductible and 20% patient coinsurance on the remaining eligible $25,500 yields patient coinsurance of $5,100 and an insurer contribution of $20,400, before considering other limits or exclusions. The patient's obligation is $5,600. If the patient later requires a separately billed $18,000 repatriation service and the policy excludes that service, the total liability could increase to $23,600. These amounts are arithmetic illustrations, not observed claims or representative tariffs.

A second hypothetical example illustrates a planned EU service. Suppose a person pays €12,000 for a home-covered treatment abroad and the home reimbursement ceiling for an equivalent service is €8,000. Under the basic ceiling logic in Article 7 of the Directive, absent more generous national provisions or other adjustments, the recoverable sum cannot exceed €8,000, leaving €4,000 paid by the patient. A separate copayment or reimbursement route could change the actual legal result. The example shows why nominal eligibility does not imply complete price protection.

Currency conversion can alter the realized burden. Let F denote a foreign-currency charge and e the domestic-currency price of one foreign-currency unit. The domestic equivalent is eF. If e rises by 10% between initial estimate and payment, then the equivalent cost rises by 10% for an unchanged F, before fees. Whether the insurer or patient bears this movement depends on the exchange-rate clause, settlement date, currency of policy limit and payment mechanism. Claims analysis must preserve the rates used instead of retrospectively applying one uniform annual exchange rate.

Provider capacity and clinical continuity

Entitlement recognition cannot create a clinician, bed, dialysis slot or specialist where a provider has no capacity. International treatment pathways depend on referral protocols, language access, transfer of diagnostic information and follow-up. A patient may be eligible for a service but face delays that make the promised right less effective. The source-grounded distinction between formal reimbursement rules and real access also appears in the European Commission's Directive evaluation.

In cross-border planned care, providers may have national licensing and quality obligations as well as treatment-specific consent requirements. Patient care after repatriation can require medication reconciliation, translation of discharge information and identification of a domestic follow-up team. A medical bill that is fully reimbursed can coexist with interrupted clinical continuity; pure claims-cost outcomes should therefore be supplemented by treatment and recovery measures.

Migrants, mobile workers and vulnerable travelers

Migration commonly changes eligibility because the person's insurance affiliation may depend on residence, employment, contribution history, recognized protection status or registration. The WHO's 2022 migration health report documents informational and administrative barriers, language obstacles, financial insecurity and fragmented measurement. A person may be entitled to enrollment yet remain effectively uninsured while documents are processed. Another person may be insured for domestic care but have no contractual protection for visiting a country of origin.

Frontier workers, internationally posted employees, students, pensioners, refugees, stateless persons and temporary visitors have different legal starting points. A statistical category such as 'foreign-born' does not identify eligibility for a particular scheme. In research, nationality, migration status and residence should be used only when necessary and lawful, with explicit assessment of discrimination and data-protection safeguards.

The international comparison indicates a distributional tension. Mobility rights may be administratively available to all qualifying members, while use of a reimbursement route requires ability to advance money, navigate foreign-language documents and absorb travel costs. The Commission's Directive evaluation identifies patient advance payment as a barrier to equitable access. Coverage generosity and real affordability must be measured jointly.

Claims coordination and jurisdiction

The claimant–provider–payer sequence

A reproducible reconstruction begins before care. The patient establishes affiliation, eligibility and benefit category; the relevant institution provides a card, registration document, authorization or policy certificate. During care, the provider verifies identity and eligibility, determines clinical necessity, records services and issues an invoice or claim. Afterwards, the responsible insurer or public institution applies tariffs, benefit limits and coordination rules, then either pays the provider or reimburses the patient.

This sequence contains multiple potential failure points: a card is expired; the person is registered in the wrong scheme; a provider is private and outside a reciprocal public system; prior authorization was required but not requested; a medical code differs between countries; the insurer demands an original invoice; or an interinstitutional invoice remains unsettled although patient treatment has occurred. These events should not be aggregated into a single legal coverage determination.

For each disputed episode, the researcher should reconstruct a timestamped chain: entitlement start and end, departure, onset of illness, first provider contact, admission, notification to assistance, authorization request, treatment, discharge, invoice, claim filing, document requests, decision, appeal and final payment. This reconstruction creates an auditable distinction between reimbursement delay, coverage exclusion, medical billing disagreement and breakdown of administrative coordination.

Interinstitutional settlement and private claims

Article 25 of Regulation 987/2009 provides mechanisms for reimbursement within EU temporary-stay coordination. In some circumstances, the institutions account for costs between themselves; in others a patient who has paid obtains reimbursement through a specified institution. The legal duty to account does not mean that every patient will receive a direct payment immediately. The relevant national provider arrangements and claims documentation govern what happens operationally.

Private travel claims may involve an insured, hospital, treating physician, assistance company, insurer, reinsurer and sometimes a card issuer or travel platform. The underlying insurance contract should identify the party liable for covered losses. Reinsurance typically allocates risk between insurers and does not, by itself, create a direct contractual promise to the traveler. Payment coordination may require invoices showing the service date, treating physician, diagnosis, currency and amounts already paid by another insurer.

A coordination-of-benefits clause can define primary and secondary responsibility when a traveler has public coverage and private supplemental insurance. Researchers must examine the actual terms rather than presume that one insurer always pays the difference. Exclusions for expenses recoverable elsewhere and subrogation or recovery rights can also affect net indemnity. Double payment is a claims-control issue, whereas incomplete payment despite multiple policies is a financial-protection issue.

Jurisdiction, applicable law and complaint routes

A cross-border dispute may involve several places: residence, contract formation, insurer authorization, place of medical service, location of the intermediary, and place of payment. Public social security administrative remedies, private insurance complaints, medical negligence proceedings and data-protection complaints may have different competent authorities. A single foreign bill can therefore generate multiple legally distinct disputes.

European cross-border healthcare legislation includes obligations concerning information and administrative cooperation; national competent authorities implement procedures within their legal systems. In the private market, the precise jurisdiction and law clause must be interpreted alongside mandatory consumer protections and applicable international private-law rules. General statements that a patient can sue only in the insurer's country or only where treatment occurred are analytically unsound.

A sound claims study records the formal refusal reason, document used for the decision, appeal period, decision maker, availability of independent complaints handling, and eventual enforcement outcome. Mere possession of an appeals channel should not be equated with timely and affordable correction. Measured success rates must separate procedural reversal, partial additional payment and full substantive satisfaction.

Consent, health data and digital interoperability

Transnational claims often require diagnoses, prescriptions, discharge summaries, identity records, bank details and supporting invoices. Under the EU General Data Protection Regulation, health information is a special category requiring an appropriate legal basis and relevant Article 9 condition, together with purpose, security and transfer safeguards. Obtaining a broad consent statement does not automatically solve all compliance obligations. Controllers must examine necessity, retention and the precise lawful channel for sharing data.

The European Health Data Space timetable establishes a gradual framework for exchange of electronic health information. Its entry into force in 2025 does not mean all priority categories became operational immediately. The Commission identifies major phased application dates beginning in 2029 for patient summaries and prescriptions and 2031 for additional categories. Researchers should not count future intended interoperability as current claims-processing capacity.

Digitization may shorten verification times, but it may also introduce mismatched patient identifiers, coding conflicts, incorrect translations or unauthorized dissemination. An evaluation should examine both processing performance and confidentiality, including the lawful minimization of health data in insurance analytics. Interoperability of clinical records should also be distinguished from interoperability of reimbursement decisions: the former may supply evidence while the latter depends on eligibility and payment law.

Distribution, disclosure and consumer understanding

Travel policies are frequently sold in bundles with transportation, accommodation or payment products. A consumer may encounter multiple definitions of 'emergency', 'hospitalization', 'trip', 'preexisting condition' and 'assistance.' The Insurance Distribution Directive overview outlines European disclosure, product-information and conduct standards. The NAIC's travel-insurance overview documents a different U.S. state-based regulatory pathway.

In an empirical product review, analysts should obtain the actual policy wording and any endorsement, not rely on advertising summaries. Record exact exclusions, reimbursement triggers, time limits for notification, medical evacuation definition, territorial scope, monetary limits, complaint mechanisms and the legal entity underwriting the coverage. A simplified comparison of one headline benefit amount has weak explanatory value.

Information quality is a measurable component of effective portability. One can test whether a traveler can correctly identify the payer, the necessary documents, the hotline, the difference between state treatment and a private hospital, and the likely need for an advance payment. This can be assessed through structured comprehension tests without presenting a new general theory of financial behavior.

Prevention of fraud, duplication and wrongful denial

Cross-border claims can involve forged invoices, duplicate reimbursements, fictitious providers and misrepresented travel dates. Risk-based auditing should use reliable provider identity, proof of treatment and objective billing records, proportionate to claim value and privacy requirements. Financial controls that prevent duplicate payment should not create arbitrary barriers for genuine emergencies or impose impossible documentation standards on hospitalized patients.

Insurers may use medical review, suspicious-pattern detection and external verification, but inconsistent coding across countries can create false anomalies. Cross-border denial-rate comparisons should distinguish intentional fraud from incomplete evidence, a legitimate medical-coding difference, a contract exclusion and incorrect administration. Validation should include review of false positives and whether people with language barriers or rare diseases are disproportionately affected.

Data, measurement and validation

Distinguishing persons, episodes, claims and reimbursements

The analytic population requires a declared unit. Let N represent eligible person-trips, E the number of foreign treatment episodes, Q submitted claims, A accepted claims and P paid claims. These quantities are not interchangeable. An individual can make multiple trips; one episode can lead to several invoices; one claim may be reopened; and a public-system encounter may never enter a commercial claims database.

A treatment-episode rate E/N is meaningful only if the trip exposure, insured population and collection period are measured consistently. A submitted-claim acceptance rate A/Q describes claims administration, not population health access. An authorized-planned-treatment request rate cannot be interpreted as the percentage of all travelers who required care. Different measures answer different scientific questions.

Price measures also need a common unit. Paid amount per claim, total episode spending and patient out-of-pocket cost answer distinct questions. International comparisons must account for local cost sharing, clinical case mix, private-provider use, currency conversion, price dates and whether figures include medical evacuation. Counts should be stratified by destination, benefit type, patient status, eligibility route and year.

Official European administrative evidence

The Commission's 2024 patient-mobility dataset summary, published in May 2026, was based on 29 of 30 contacted countries. It reports that 19 of 27 EU Member States operated a prior-authorization system, 12 of 27 used prior notification, and 74.7% of relevant cross-border healthcare authorization requests were approved. The percentage refers to an administrative request denominator, not all patients, procedures or costs. The report also identifies neighboring-country movements as important.

An earlier Commission report for reference year 2022 was based on 28 responses from 30 contacted countries and reported a higher share of authorized requests, alongside variations in national procedures. A simple comparison of two headline authorization percentages is insufficient to establish a causal deterioration in access. Country reporting coverage, application populations, medical case mix, policy revisions and definitions must be held comparable before a time-trend inference is warranted.

The 2022 Commission evaluation and its staff working analysis identify limited awareness, administrative friction, uncertainty and up-front costs. Together with the 2024 administrative data, these sources support a bounded finding: access rules exist and are used, while actual claim and patient pathways remain sensitive to implementation. They do not provide a global figure for all insured cross-border emergencies.

Descriptive design and causal identification

A valid comparative study should state whether it estimates the prevalence of foreign care, financial protection conditional on a need for treatment, the effect of a regulatory change, or complaint-resolution performance. A cross-sectional difference between two countries cannot by itself identify the effect of portability rules because health status, traveler income, destination choice, migration composition, provider costs and administrative reporting can differ simultaneously.

For a policy reform with a known implementation date, event-study or difference-in-differences designs may be appropriate if a credible comparison group and parallel pretrends exist. Investigators must examine anticipatory behavior, legal transitions, changes in coding and concurrent travel disruptions. An interrupted-time-series model is particularly sensitive to global shocks that alter travel volume and medical utilization. Whenever assumptions cannot be supported, results should be reported as descriptive associations.

Survey evidence should sample people unable to obtain treatment as well as paid claims. Claims datasets typically condition on a claim being submitted and may systematically omit persons who paid and never claimed, abandoned care, or were refused a hospital admission. Provider records and travel exposure surveys can improve coverage, subject to consent and data-protection constraints.

Exposure-adjusted claims analysis

Define trip-specific medical claim frequency by destination d and time period t as f(d,t) = C(d,t)/N(d,t), where C is the number of distinct claim-generating medical episodes and N is insured person-trips or exposure-weighted trip-years. Mean severity is s(d,t) = L(d,t)/C(d,t), where L is total eligible paid loss in a consistent currency and on a consistent incurred/payment basis. The arithmetic identity f × s = L/N holds with aligned definitions and positive counts. This is an actuarial identity, not a novel pricing theory.

Expected losses may depend on age composition, trip duration, destination costs, declared activities, conditions, currency and evacuation pathways. A model that estimates frequency without policy duration will confuse long trips with intrinsically high risk. A severity model excluding large losses by applying a low internal cap can conceal important catastrophic medical or evacuation exposure. Loss adjustment expenses, assistance fees, insurer operating costs and risk margin must be distinguished from paid clinical benefits when analyzing premium adequacy.

Out-of-pocket protection requires a separate measure. Let B be an eligible provider bill, I indemnity paid by the public or private payer, and X patient payments for covered and excluded items; verify that accounting categories reconcile and avoid double counting copayments or advance payments later refunded. A reported gross B−I difference is not necessarily the final patient burden if another payer contributes, a reimbursement is pending, or an excluded nonmedical service appears in the invoice.

Worked financial and actuarial illustrations

Assume a hypothetical dataset of 2,000 distinct covered person-trips and 80 medical episodes in a single defined exposure period. Claim frequency is 80/2,000 = 0.04 episodes per person-trip. If total eligible paid medical claims are $240,000, mean paid severity is $3,000 per episode and average paid cost is $120 per person-trip. These numbers are synthetic and contain no population inference.

Now suppose one additional evacuation claim of $160,000 is included, yielding 81 episodes and $400,000 total payment. Average paid cost increases to $200 per trip; observed frequency becomes 81/2,000 = 0.0405, while mean severity rises to approximately $4,938.27. The loss-cost rise is 66.7% even though episode frequency increases only 1.25% relative to 80. This demonstration shows the sensitivity of pooled averages to rare high-value claims; it does not establish any true evacuation probability.

Consider a separate illustrative comparison of two public reimbursement arrangements. A service costs €10,000 in the treatment country. Arrangement A directly recognizes €9,000, with €1,000 paid by the member. Arrangement B reimburses €6,000 after the member advances €10,000, ultimately leaving €4,000. The difference is both €3,000 in final burden and €10,000 versus €1,000 in initial liquidity demand. A dataset recording only eventual payer contributions would miss the temporary financing barrier.

The numerical examples also illustrate why a travel insurance limit alone is not a sufficient measurement. Insured amounts, eligible service definitions, policy deductible, deductible accumulation and payment timing jointly determine financial protection. Each hypothetical uses a specified calculation rather than claiming a universal treaty or policy clause.

Sensitivity, missingness, selection and quality checks

Every comparative estimate should have a data dictionary that specifies eligibility, unit, country, policy year, treatment date, payment date, payer, public/private provider, diagnosis group and benefit category. Data quality assessment should quantify missing invoices, incomplete country identifiers, unresolved claims and claims paid after the observation cutoff. If pending claims are excluded, the analyst should estimate a reasonable development adjustment or state the resulting downward bias.

For financial sensitivity, examine exchange-rate scenarios, different severity-tail assumptions, alternative eligible-benefit definitions, a change in underreporting of low-cost claims and separate evacuation losses. For causal sensitivity, test alternative comparison areas, preperiods and negative-control outcomes. For fairness assessment, disaggregate qualified status categories and payment results where lawful and statistically supported, while protecting confidentiality.

The WHO's migration evidence review indicates persistent information gaps. The WHO's global monitoring programme uses distinct population denominators for health service coverage and financial hardship. Neither indicator should be imported as the denominator of travel claims without a purpose-specific redefinition. Reproducibility requires documenting exactly where an external statistic enters an analysis and what question it can support.

International synthesis and scientific conclusions

Comparative institutional findings

The jurisdictions examined establish several defensible observations. European coordination may preserve competent-system liability while host providers deliver necessary services, and a separate patient-rights route may reimburse home-entitled planned care up to applicable ceilings. The United Kingdom operates destination- and eligibility-dependent reciprocal mechanisms. Australia's bilateral agreements cover necessary care only within their individual scopes. Canada's provincial arrangements frequently leave substantial foreign price exposure. Original Medicare ordinarily has narrow foreign coverage. Commercial travel health insurance depends on policy terms, benefit categories and claim mechanics.

These legal systems implement different types of portability. A reciprocal arrangement can reduce the patient's need to advance money and use familiar administrative contacts. A reimbursement right can be legally valuable while producing a temporary liquidity burden. A private policy can cover a high-cost emergency unavailable through reciprocal public systems, yet exclude the medical evacuation required by that case unless purchased or expressly included.

The institutional analysis by Legido-Quigley and colleagues and patient-mobility classification by Glinos and colleagues help explain why motive and payment pathway matter. The present synthesis extends the source comparison across temporary travelers and residency transitions while respecting the narrower subjects of the original studies. No systematic estimate is made of global coverage prevalence or of the net welfare effect of all portability provisions.

Inferences and rival explanations

The strongest analytic inference is that portability effectiveness must be tested through both entitlement and realized payment/access. A national rule may recognize a patient's claim while the claim fails operationally because of documentation, currency, advance payment or provider-side constraints. This inference is supported by official European administrative findings and the broader migration-health literature, though exact causal effects require separate studies.

Several alternative explanations matter. A country with more foreign claims may have more cross-border trips, better documentation, more expensive providers, more complete reporting, greater access or more fragmented domestic care. A country with fewer refusals may screen out would-be applicants before submission. A country with lower average medical claim costs may exclude evacuation losses or reimburse only public tariffs. These rival pathways preclude rankings from raw aggregates.

An important distributive implication follows from the difference between final reimbursement and liquidity. Two members with the same nominal right may face different access if one can advance a large provider charge and the other cannot. In travel insurance, direct settlement with credible local hospitals may therefore affect accessibility even when ultimate benefit limits are unchanged. A scientifically useful comparison must measure this operational dimension rather than infer it from a policy's printed maximum.

Research agenda and implementation implications

Future empirical work can link anonymized eligibility records, trip exposures, hospital encounters, public settlement records and commercial claims, subject to lawful data access. A feasible study would stratify by temporary stay, planned treatment, newly resident migrant, frontier worker and other identified status. It would compare both paid and unpaid episodes, authorized and denied applications, assistance response times, effective patient spending and access delays.

A second research direction is a matched comparison of direct-settlement availability across destinations, with careful adjustment for provider network, case mix and traveler income. A third is administrative study of planned-care authorization changes under national legal revisions, using pre-specified treatment groups and comparable application definitions. A fourth concerns health-data interoperability: evaluate whether improved clinical information exchange measurably reduces claims friction while meeting health-data security and privacy requirements.

For institutions, the evidence supports clear eligibility notices, reliable pretravel verification, clinically informed authorization, transparent tariff explanations, accessible assistance channels, proportionate documentation, explicit financial responsibility and meaningful appeals. For private insurers and intermediaries, claim-language clarity and accurate distinction between medical, evacuation and disruption benefits are central. These are operational implications of documented arrangements, not declarations of a new binding doctrine.

Scope and methodological limitations

This is a comparative documentary monograph with selected peer-reviewed scholarship and reproducible hypothetical numerical examples. The primary legal and official sources were examined at the link and relevant provision or summary level as recorded in the accompanying evidence ledger. The paper does not conduct a census of national implementing laws, insurer policies, bilateral amendments, provider contracts, or court decisions across the world. Some academic articles were inspected through verified abstracts and bibliographic records rather than inaccessible paywalled full text.

The reviewed empirical figures come from European administrative surveys, not a linked international patient dataset. The numbers cannot estimate worldwide incident emergency rates, causal effects of universal portability or insurance product-specific loss ratios. Treaty applicability, contract exclusions, local obligations, and patient-specific legal remedies are facts requiring fresh jurisdiction- and date-specific review. No external peer review, original clinical investigation or unpublished insurer microdata analysis is claimed.

Conclusion

Cross-border health insurance portability is a set of legally and financially specific pathways through which a person may obtain healthcare beyond the ordinary territory of health coverage. EU temporary-stay coordination, authorized planned-care procedures, Directive 2011/24/EU reimbursements, UK reciprocal rights, Australia's bilateral agreements, Canadian provincial benefits, U.S. Medicare exceptions and private travel medical contracts each allocate risk and payment differently. Their shared empirical challenge is translating a qualifying entitlement into timely, affordable and clinically appropriate treatment.

The source record supports six conclusions. Eligibility depends on the applicable scheme and personal situation; medically necessary temporary-stay care has a different legal trigger from planned care; home-tariff reimbursement can leave a significant foreign-price gap; repatriation and evacuation require separately established coverage; claims processing and initial liquidity can affect real access; and empirical comparisons require aligned units, periods, jurisdictions and reporting coverage. European administrative studies further show that formal rights can coexist with substantial practical barriers.

The monograph's scientific contribution is a source-attributed synthesis of established legislation, empirical research, claims operations, actuarial identities and measurement limitations. Its analytical conclusions are testable through appropriately designed future comparative work. The work is complete as an internal research manuscript and reserved for a separate publishing decision.

References